OncoMatch/Clinical Trials/NCT07144254
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Is NCT07144254 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Tegavivint and Gemcitabine for osteosarcoma recurrent.
Treatment: Tegavivint · Gemcitabine — The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Prior therapy
Must have received: cytotoxic chemotherapy (methotrexate, doxorubicin, cisplatin, ifosfamide) — front-line
front-line treatment with a regimen that contained at least 3 of the following agents: methotrexate, doxorubicin, cisplatin, and ifosfamide
Cannot have received: tegavivint (tegavivint)
Patients who have previously received tegavivint are not eligible.
Lab requirements
Blood counts
Peripheral ANC ≥ 750/mm3; Platelet count ≥ 75,000/mm3
Kidney function
Creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73 m2
Liver function
Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x ULN for age; ALT ≤ 5 x ULN
Cardiac function
QTc ≤ 470 ms using Fridericia formula
Adequate Bone Marrow Function...Adequate Renal Function...Adequate Liver Function...Adequate Pulmonary Function...Adequate Cardiac Function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arthur M. Blank Children's Healthcare of Atlanta · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify